Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

NCT03302728 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Hodgkin Lymphoma

Interventions

DRUG: Lenalidomide 15mg
DRUG: Brentuximab Vedotin 1.8 mg/Kg

Sponsor

Peter MacCallum Cancer Centre, Australia